Clinicogenomic Landscape of Pancreatic Ductal Adenocarcinoma: The Prognostic Role of KRAS Mutation Dosage Academic Background Pancreatic ductal adenocarcinoma (PDAC), the most common histological type of pancreatic cancer, is the third leading cause of cancer-related mortality and has the lowest five-year survival rate among all cancer types. Over ...
Neuropathic Changes in Pancreatic Cancer Academic Background Pancreatic cancer is one of the most lethal cancers today, characterized by late diagnosis and high aggressiveness. Despite some progress in diagnosis and treatment in recent years, the five-year survival rate for pancreatic cancer remains extremely low, at only around 12%. The pathogenes...
New Method for Early Detection of Pancreatic Cancer—A Protease-Activated Nanosensor Assay Background Pancreatic Ductal Adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths worldwide. Due to its nonspecific early symptoms, most patients are diagnosed at advanced stages, resulting in limited treatment options and poor prognosis...
Targeting Chemotherapy-Induced Adaptive Signaling Circuitry for Therapeutic Potential in Pancreatic Cancer Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer, with a five-year survival rate that remains extremely low. Over 80% of patients are diagnosed at an advanced, unresectable stage, where existin...
Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...
Progress in Cancer Research: Inhibitory Mechanisms and Effects of Erianin on Pancreatic Cancer Background and Significance of the Study Pancreatic cancer is a malignant tumor of the digestive tract, characterized by inconspicuous early symptoms, high malignancy, and limited efficacy of conventional radiotherapy and chemotherapy, leading to a very h...
Background Pancreatic Ductal Adenocarcinoma (PDAC) is a malignancy with a highly immunosuppressive tumor microenvironment (TME), showing strong resistance to immune checkpoint blockade (ICB) therapies, such as anti-PD-1 and anti-CTLA-4 treatments. Myeloid-Derived Suppressor Cells (MDSCs) derived from tumors play a critical role in tumor immune supp...
Research Report on the Mechanism of BAG6 Restricting Pancreatic Cancer Progression Research Background Pancreatic Ductal Adenocarcinoma (PDAC) has an extremely poor prognosis, with a median survival of only 6 months, urgently requiring new treatment methods. In recent years, studies have found that extracellular vesicles (EVs) released by tumor cel...
Research Report: The Regulatory Role of ROR2 in Pancreatic Cancer Cell Plasticity Background Introduction Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with most patients lacking the possibility of a cure. This is partly due to the difficulty in early detection. One of the characteristics of PDAC is its extensive tumor cell heterogene...
Interactive Mechanisms Between Cancer Cells and Macrophages Facilitate Pancreatic Cancer Cachexia Background Pancreatic cancer is currently the third leading cause of cancer-related death in the United States and is expected to become the second leading cause of cancer death within the next decade. Unfortunately, more than 80% of pancreatic cancer ...